<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Elderly medication adherence &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/elderly-medication-adherence/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 24 Jan 2026 00:44:11 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Elderly medication adherence &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>高齢者の骨粗鬆症治療の持続性比較</title>
		<link>https://bioengineer.org/%e9%ab%98%e9%bd%a2%e8%80%85%e3%81%ae%e9%aa%a8%e7%b2%97%e9%ac%86%e7%97%87%e6%b2%bb%e7%99%82%e3%81%ae%e6%8c%81%e7%b6%9a%e6%80%a7%e6%af%94%e8%bc%83/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 24 Jan 2026 00:43:47 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Elderly medication adherence]]></category>
		<category><![CDATA[Geriatric bone health** * **Osteoporosis treatment persistence:** Makalenin ana konusu]]></category>
		<category><![CDATA[İlaç devamlılık oranları]]></category>
		<category><![CDATA[İşte 5 uygun etiket: **Osteoporoz tedavisi]]></category>
		<category><![CDATA[İşte içerik için uygun 5 etiket: **Osteoporosis treatment persistence]]></category>
		<category><![CDATA[Japanese cohort study]]></category>
		<category><![CDATA[Japon yaşlı nüfusu]]></category>
		<category><![CDATA[Kohort çalışması** **Açıklama:** 1. **Osteoporoz tedavisi:** Makalenin ana konusu. 2. **İlaç devamlılık oran]]></category>
		<category><![CDATA[Romosozumab vs Teriparatid]]></category>
		<category><![CDATA[Romosozumab vs Teriparatide]]></category>
		<category><![CDATA[tedavilerin devamlılık oranlarının karşılaştırılması. * **Romosozumab vs Teriparatide:** Karşı]]></category>
		<guid isPermaLink="false">https://bioengineer.org/%e9%ab%98%e9%bd%a2%e8%80%85%e3%81%ae%e9%aa%a8%e7%b2%97%e9%ac%86%e7%97%87%e6%b2%bb%e7%99%82%e3%81%ae%e6%8c%81%e7%b6%9a%e6%80%a7%e6%af%94%e8%bc%83/</guid>

					<description><![CDATA[In the realm of osteoporosis treatment, two medications emerge as significant players: romosozumab and teriparatide. These drugs are instrumental in combating bone loss among older adults, particularly among the Japanese population aged 75 years and older, who are often at heightened risk for osteoporosis. A new cohort study led by researchers Yoshiyama, Fukasawa, and Masuda [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">320085</post-id>	</item>
	</channel>
</rss>
